| 5.895 -0.005 (-0.08%) | 06-02 11:40 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.58 | 1-year : | 9.92 |
| Resists | First : | 7.34 | Second : | 8.5 |
| Pivot price | 6.19  |
|||
| Supports | First : | 5.48 | Second : | 4.55 |
| MAs | MA(5) : | 5.93 |
MA(20) : | 6.6 |
| MA(100) : | 6.3 |
MA(250) : | 6.04 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14 |
D(3) : | 15.1 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VRCA ] has closed above bottom band by 37.1%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.11 - 6.14 | 6.14 - 6.18 |
| Low: | 5.57 - 5.62 | 5.62 - 5.66 |
| Close: | 5.84 - 5.9 | 5.9 - 5.96 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Thu, 28 May 2026
Skin disease drug CEO to speak at New York Jefferies event - Stock Titan
Thu, 28 May 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Sahm
Tue, 26 May 2026
H.C. Wainwright Initiates Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Announces Target Price $12 - Moomoo
Tue, 12 May 2026
Verrica Pharmaceuticals (VRCA) Q1 2026: EPS Not Disclosed (Est - - GuruFocus
Tue, 12 May 2026
Verrica (NASDAQ: VRCA) Q1 revenue hits $5.0M as YCANTH demand grows - Stock Titan
Tue, 12 May 2026
Childhood molluscum YCANTH tops 100,000 applicator units, launches in Japan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 48.6 (%) |
| Held by Institutions | 27.8 (%) |
| Shares Short | 412 (K) |
| Shares Short P.Month | 581 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | -48 % |
| Operating Margin | -193.5 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 46 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 2.16 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -5.4 |
| PEG Ratio | 0 |
| Price to Book value | 4.11 |
| Price to Sales | 2.74 |
| Price to Cash Flow | -7.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|